• Explore /
  • Poster
  • / Clinical outcomes by <em>SF3B1</em> mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).

Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).

Abstract Poster

Authors

null

Adeola Y. Makinde

Bristol Myers Squibb, Princeton, NJ

Adeola Y. Makinde , Guillermo Garcia-Manero , Rayna K. Matsuno , Ali McBride , Thomas D. Brown , Danny Idryo , Ronda Broome , Autumn Herriman , Kristiana Wilkinson , Sheetal Walters , Andrew Schrag , Hina Mohammed , Monika A. Izano , Sudipto Mukherjee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Other Leukemia, Myelodysplastic Syndromes, and Allotransplant

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7071)

DOI

10.1200/JCO.2023.41.16_suppl.7071

Abstract #

7071

Poster Bd #

201

Abstract Disclosures

Similar Posters

First Author: Steven Gilmore

First Author: Sudipto Mukherjee

First Author: Uwe Platzbecker

First Author: Helen H. Moon